dc.contributor.author |
Maciag, Anna E. |
en_US |
dc.contributor.author |
Holland, Ryan J. |
en_US |
dc.contributor.author |
Saavedra, Joseph E. |
en_US |
dc.contributor.author |
CHAKRAPANI, HARINATH |
en_US |
dc.contributor.author |
Shami, Paul J. |
en_US |
dc.contributor.author |
Keefer, Larry K. |
en_US |
dc.date.accessioned |
2021-01-15T05:45:29Z |
|
dc.date.available |
2021-01-15T05:45:29Z |
|
dc.date.issued |
2012 |
en_US |
dc.identifier.citation |
Onco Therapeutics, 3(2). |
en_US |
dc.identifier.issn |
2694-4642 |
en_US |
dc.identifier.issn |
2694-4650 |
en_US |
dc.identifier.uri |
http://dr.iiserpune.ac.in:8080/xmlui/handle/123456789/5521 |
|
dc.identifier.uri |
https://doi.org/10.1615/ForumImmunDisTher.2012006334 |
en_US |
dc.description.abstract |
Promising drug candidates of the diazeniumdiolate (NONOate) chemical family include several types of thiol modification among their mechanisms of action: 1) drugs designed to release nitric oxide (NO) on reaction with the thiol group of glutathione (GSH) arylate the GSH, a step that removes reducing equivalents from the cell; (2) a similar reaction of the drug with the thiol group of a protein changes its structure, leading to potentially impaired function and cell death; (3) the NO generated as a byproduct in the above reactions can undergo oxidation, leading to S-nitrosylation and S-glutathionylation; and (4) diazeniumdiolates can also generate nitroxyl, which reacts with thiol groups to form disulfides or sulfinamides. |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
Begell |
en_US |
dc.subject |
Thiol |
en_US |
dc.subject |
Nitric oxide |
en_US |
dc.subject |
Diazeniumdiolate |
en_US |
dc.subject |
2012 |
en_US |
dc.title |
Thiol Modification By Pharmacologically Active Agents of the Diazeniumdiolate Class |
en_US |
dc.type |
Article |
en_US |
dc.contributor.department |
Dept. of Chemistry |
en_US |
dc.identifier.sourcetitle |
Onco Therapeutics |
en_US |
dc.publication.originofpublisher |
Foreign |
en_US |